Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 3CNS 2Thoracic 1Breast 1

Conditions

Brain Neoplasms 14Glioblastoma 6Neoplasms 4Lymphoma, Non-Hodgkin 4Breast Neoplasms 4Testicular Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Neoplasm Metastasis 3Meningeal Carcinomatosis 3Lymphoma 3Glioma 3Burkitt Lymphoma 3Vomiting 2Testicular Germ Cell Tumor 2Sezary Syndrome 2Recurrence 2Radiation Injuries 2Primary Myelofibrosis 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Oligodendroglioma 2Nausea 2Myeloproliferative Disorders 2Mycosis Fungoides 2Multiple Myeloma 2Melanoma 2Medulloblastoma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2

Interventions

Radiosurgery 22Nivolumab 21Ipilimumab 19pembrolizumab 15Temozolomide 11dabrafenib 10binimetinib 10encorafenib 8Cyclophosphamide 8trametinib 7Magnetic Resonance Spectroscopy 7Bevacizumab 6fludarabine 5cobimetinib 5Specimen Handling 5CTLA-4 Antigen 5fludarabine phosphate 3aldesleukin 3Vemurafenib 3Thalidomide 3Paclitaxel 3Oxaliplatin 3Interleukin-2 3Gemcitabine 3Drug Therapy 3Carboplatin 3130-nm albumin-bound paclitaxel 3ulixertinib 2tovorafenib 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Dexamethasone × CNS × Clear all
NCT02709889 2020-10-19

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

AbbVie

Phase 1/2 Terminated
200 enrolled 21 charts
CNSDermatologic

Glioblastoma, Melanoma, Carcinoma, Medullary

NCT04001725 2019-11-13

OPTIMAL

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown
110 enrolled
BreastCNSDermatologicThoracic

Brain Neoplasms, Breast Neoplasms, Diabetes Mellitus, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡